Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
GlaxoSmithKline
>
Dulera
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 3545886"]If they didn't see (or tell you about) Dulera getting approved, either GSK 'Leadership' was clueless about the market or hiding the truth from the field. Neither of which would be surprising.</p><p><br /></p><p>This drug will hurt GSK big time, in numerous ways.</p><p><br /></p><p>1. Now there are three drugs where there used to be one, & the pressure to reduce price will be huge. Someone, probably Symbicort because it's the weakest product of the three will undercut the managed care contracting price significantly. It's less profit or less volume, neither one is good for GSK.</p><p><br /></p><p>2. Specialists will embrace Dulera much quicker than Symbicort because Asmanex is a better Steroid than budesinide. </p><p><br /></p><p>3. Additionally, Schering (most Merck resp. specialty reps are Schering heritage) has had a long term presence with PUDs, Allergists and Peds for many years, where Astra Zeneca did not have those relationships to launch Symbicort.</p><p><br /></p><p>4. More samples on the shelves (from 3 competing drugs) mean that lots of business will walk out the door in sample bags. Long gone are the days where a rep could manage volume by starving an Advair supporter of samples.</p><p><br /></p><p>5. In many cases, lots of docs lost the rep that actually drove the business in the last re-org.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 3545886"]If they didn't see (or tell you about) Dulera getting approved, either GSK 'Leadership' was clueless about the market or hiding the truth from the field. Neither of which would be surprising. This drug will hurt GSK big time, in numerous ways. 1. Now there are three drugs where there used to be one, & the pressure to reduce price will be huge. Someone, probably Symbicort because it's the weakest product of the three will undercut the managed care contracting price significantly. It's less profit or less volume, neither one is good for GSK. 2. Specialists will embrace Dulera much quicker than Symbicort because Asmanex is a better Steroid than budesinide. 3. Additionally, Schering (most Merck resp. specialty reps are Schering heritage) has had a long term presence with PUDs, Allergists and Peds for many years, where Astra Zeneca did not have those relationships to launch Symbicort. 4. More samples on the shelves (from 3 competing drugs) mean that lots of business will walk out the door in sample bags. Long gone are the days where a rep could manage volume by starving an Advair supporter of samples. 5. In many cases, lots of docs lost the rep that actually drove the business in the last re-org.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
GlaxoSmithKline
>
Dulera
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
GlaxoSmithKline
>
Dulera
>